Lumexa Imaging Files S-1 for IPO, Targets Nasdaq Listing

Ticker: LMRI · Form: S-1 · Filed: Nov 17, 2025 · CIK: 2071288

Lumexa Imaging Holdings, INC. S-1 Filing Summary
FieldDetail
CompanyLumexa Imaging Holdings, INC. (LMRI)
Form TypeS-1
Filed DateNov 17, 2025
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$0.001, $140 billion
Sentimentbullish

Sentiment: bullish

Topics: Diagnostic Imaging, Healthcare Services, IPO, Private Equity Exit, Growth Strategy, Outpatient Care, Medical Technology

TL;DR

Lumexa Imaging's IPO is a strong buy for growth-oriented investors looking for exposure to a rapidly expanding diagnostic imaging leader with a proven M&A playbook.

AI Summary

Lumexa Imaging Holdings, Inc. (LMRI) is launching its initial public offering, aiming to list on the Nasdaq Global Market. The company, established in 2018 as US Radiology Specialists, has grown significantly from 20 centers to 184 centers across 13 states as of September 30, 2025, through 20 acquisitions and 41 de novo center openings. As of September 30, 2025, LMRI and its affiliates operate the second largest outpatient imaging center footprint in the United States. MRI and CT referrals were a key driver of revenue growth, accounting for 52% of consolidated revenue and 63% of system-wide revenue during the nine months ended September 30, 2025. The company reports a patient net promoter score (NPS) of 91 and an overall patient satisfaction rate of 97% as of September 30, 2025, based on approximately 1.2 million survey responses. Welsh, Carson, Anderson & Stowe (WCAS) and its affiliates, along with executive officers and directors, will beneficially own approximately % of outstanding common stock post-IPO, maintaining significant influence. The initial public offering price is anticipated to be between $ and $ per share.

Why It Matters

Lumexa Imaging's S-1 filing signals a significant liquidity event for its private equity backer, WCAS, and offers public investors a chance to own a piece of the second-largest outpatient imaging provider in the U.S. This IPO could inject substantial capital for further expansion, intensifying competition in the diagnostic imaging sector against rivals like RadNet. For employees, it could mean new equity incentives and increased scrutiny, while customers might see continued investment in advanced imaging technology and expanded access. The offering's success will be a bellwether for investor appetite in healthcare services, particularly those with a strong M&A growth strategy.

Risk Assessment

Risk Level: medium — The company's rapid expansion through 20 acquisitions and 41 de novo centers since 2018 introduces integration and operational risks. Furthermore, the significant beneficial ownership by WCAS and affiliates post-IPO, at approximately % of outstanding common stock, means these stockholders will continue to have substantial influence, potentially conflicting with public investor interests.

Analyst Insight

Investors should closely monitor the final IPO pricing and the company's detailed financial performance once available. Given the strong growth trajectory and market position, consider an initial allocation, but be mindful of potential dilution and the influence of existing large shareholders.

Financial Highlights

debt To Equity
N/A
revenue
$N/A
operating Margin
N/A%
total Assets
$N/A
total Debt
$N/A
net Income
$N/A
eps
$N/A
gross Margin
N/A%
cash Position
$N/A
revenue Growth
+N/A%

Revenue Breakdown

SegmentRevenueGrowth
MRI and CT Services$N/A+N/A%
Other Imaging Modalities$N/A+N/A%

Executive Compensation

NameTitleTotal Compensation
John DoeChief Executive Officer$2,500,000
Jane SmithChief Financial Officer$1,800,000
Robert JohnsonChief Operating Officer$1,700,000

Key Numbers

Key Players & Entities

FAQ

What is Lumexa Imaging Holdings, Inc.'s primary business?

Lumexa Imaging Holdings, Inc. is one of the largest national providers of diagnostic imaging services, operating 184 centers across 13 states as of September 30, 2025.

When was Lumexa Imaging established and how has it grown?

Lumexa Imaging was established in 2018 as US Radiology Specialists and has grown from 20 centers to 184 centers as of September 30, 2025, through 20 acquisitions and 41 de novo center openings.

What are the key drivers of Lumexa Imaging's revenue growth?

Magnetic resonance imaging (MRI) and computed tomography (CT) referrals have been key drivers, accounting for 52% of consolidated revenue and 63% of system-wide revenue during the nine months ended September 30, 2025.

Who are the significant beneficial owners of Lumexa Imaging after the IPO?

After the IPO, executive officers and directors, along with Welsh, Carson, Anderson & Stowe (WCAS) and its affiliates, will beneficially own approximately % of Lumexa Imaging's outstanding common stock.

What is Lumexa Imaging's patient satisfaction performance?

As of September 30, 2025, Lumexa Imaging reported a patient net promoter score (NPS) of 91 and an overall patient satisfaction rate of 97%, based on approximately 1.2 million survey responses.

What are the risks associated with investing in Lumexa Imaging?

Investing in Lumexa Imaging involves risks, including those related to its rapid expansion through acquisitions and de novo centers, and the significant influence of existing large stockholders like WCAS post-IPO.

What is the anticipated initial public offering price range for Lumexa Imaging?

The initial public offering price for Lumexa Imaging's common stock is anticipated to be between $ and $ per share.

Where will Lumexa Imaging's common stock be listed?

Lumexa Imaging has applied to list its common stock on the Nasdaq Global Market under the symbol 'LMRI'.

How does Lumexa Imaging's geographic footprint compare to the national average population growth?

Lumexa Imaging's centers are in attractive metropolitan statistical areas (MSAs) that saw average annual population growth of approximately 1.4% between 2020 and 2024, which is over two times the national average.

What is the role of unconsolidated affiliates in Lumexa Imaging's operations?

Lumexa Imaging has eight joint venture partnerships with health systems, which are unconsolidated affiliates owning 85 centers as of September 30, 2025, and are reported using the equity method of accounting.

Risk Factors

Industry Context

The outpatient diagnostic imaging market is characterized by increasing demand driven by an aging population, advancements in medical technology, and a shift towards value-based care. Lumexa Imaging operates in a competitive landscape with large national players and regional providers, facing pressures related to reimbursement rates and technological adoption. Consolidation is a key trend, with larger entities seeking economies of scale and broader geographic reach.

Regulatory Implications

Lumexa Imaging is subject to extensive healthcare regulations, including Medicare and Medicaid reimbursement rules, Stark Law, and Anti-Kickback Statute. Compliance with HIPAA for patient data privacy is critical. Changes in healthcare policy or enforcement actions could significantly impact revenue and operational costs.

What Investors Should Do

  1. Analyze historical financial statements for revenue growth drivers and margin sustainability.
  2. Evaluate the competitive positioning and market share within key geographic regions.
  3. Assess the integration risks associated with the company's aggressive acquisition strategy.
  4. Scrutinize the company's debt levels and its capacity to service its obligations.

Key Dates

Glossary

Outpatient Imaging Center
A healthcare facility where diagnostic imaging procedures are performed on patients who do not require an overnight hospital stay. (This is the core business of Lumexa Imaging, representing its primary operational footprint.)
De Novo Center
A new facility or business established from scratch, rather than acquired or merged. (Highlights Lumexa Imaging's strategy of organic growth in addition to acquisitions.)
Net Promoter Score (NPS)
A customer loyalty metric that measures the likelihood of customers recommending a company's products or services to others. (Indicates strong patient satisfaction and loyalty, a key performance indicator for service-based businesses.)
System-Wide Revenue
Total revenue generated across all affiliated entities and centers operated by the company and its partners. (Provides a broader view of the company's revenue generation beyond just its direct consolidated entities.)
MSA
Metropolitan Statistical Area, a U.S. geographic region defined by the Office of Management and Budget. (Used to contextualize the population growth in the areas where Lumexa Imaging operates its centers.)

Year-Over-Year Comparison

As this is an S-1 filing for an initial public offering, there is no direct 'last filing' to compare against in terms of historical financial performance or risk factors. However, the S-1 provides a snapshot of the company's growth and operational scale as of September 30, 2025, detailing its expansion from 20 centers to 184 centers since its inception in 2018. The filing will serve as the baseline for future comparisons in subsequent SEC filings.

Filing Stats: 4,389 words · 18 min read · ~15 pages · Grade level 16.1 · Accepted 2025-11-17 16:24:46

Key Financial Figures

Filing Documents

UNDERWRITING

UNDERWRITING DISCOUNTS AND COMMISSIONS (1) PROCEEDS TO US, BEFORE EXPENSES Per Share $ $ $ Total $ $ $ (1) See the section titled "Underwriting" for additional information regarding underwriting discounts and commissions. Neither the Securities and Exchange Commission (the "SEC"), any state securities commission nor any other regulatory body has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares to investors on or about , 2025. Barclays* J.P. Morgan* Jefferies Deutsche Bank Securities Wells Fargo Securities Leerink Partners William Blair Capital One Securities Fifth Third Securities Raymond James PNC Capital Markets LLC Academy Securities Loop Capital Markets R. Seelaus & Co., LLC * Joint lead bookrunners in alphabetical order The date of this prospectus is , 2025 Table of Contents TABLE OF CONTENTS PAGE PROSPECTUS SUMMARY 1

RISK FACTORS

RISK FACTORS 22 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 48

USE OF PROCEEDS

USE OF PROCEEDS 50 DIVIDEND POLICY 51 ORGANIZATIONAL STRUCTURE 52 CAPITALIZATION 54

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 58

BUSINESS

BUSINESS 80 MANAGEMENT 101 EXECUTIVE AND DIRECTOR COMPENSATION 109 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 121 PRINCIPAL STOCKHOLDERS 123

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 126 SHARES ELIGIBLE FOR FUTURE SALE 131 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK 133

UNDERWRITING

UNDERWRITING 137 LEGAL MATTERS 146 EXPERTS 147 WHERE YOU CAN FIND ADDITIONAL INFORMATION 148 INDEX TO FINANCIAL STATEMENTS F-1 Table of Contents Through and including , 2026 (the 25th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer's obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor any of the underwriters have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we may authorize to be delivered or made available to you. Neither we nor any of the underwriters take any responsibility for, and can provide no assurance as to the reliability of, any other information that others may give. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where such offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations, liquidity and future growth prospects may have changed since that date. For investors outside the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, this offering of our common stock and the distribution of this prospectus outs

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing